In 2018, the U.S. Food and Drug Administration (FDA) invited comments on its intention to exempt a list of class II devices from premarket notification requirements, including tests assessing genetic health risks. ASHG responded to this request for comment by outlining its support for regulation that brings scientifically valid, evidence-based tests to market, and expressing... Read More
For Immediate Release Thursday, August 3, 2017 12:00 p.m. U.S. Eastern Time Media Contact: Nalini Padmanabhan ASHG Communications Manager 301.634.7346 press@ashg.org Medical, Research, and Counseling Groups Issue Statement on Germline Genome Editing BETHESDA, MD – An international group of 11 organizations with genetics expertise has issued a policy statement on germline genome editing in humans,... Read More
I am delighted to announce that ASHG’s statement on germline genome editing was published today in The American Journal of Human Genetics. This statement, written by a workgroup co-led by Kelly Ormond and Doug Mortlock and approved by ASHG’s Board of Directors, gives the Society’s perspective on the use of CRISPR/Cas9 or other similar tools... Read More
In 2017, ASHG and 10 international organizations published a position statement on human germline genome editing in The American Journal of Human Genetics. The statement recommended against genome editing culminating in human pregnancy, supported publicly funded in vitro research into its potential clinical applications, and outlined scientific and societal steps necessary before implementation of such... Read More
Media Contact: Nalini Padmanabhan ASHG Communications Manager 301.634.7346 press@ashg.org For Immediate Release Thursday, March 9, 2017 12:00 pm U.S. Eastern Time BETHESDA, MD – The American Society of Human Genetics (ASHG) applauds yesterday’s passage of S-201, the Genetic Non-Discrimination Act, in a 222-60 vote by the Parliament of Canada’s House of Commons. Because of minor... Read More